2257.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 05:41):

Stats
Dagens volum	2.99M
Gjennomsnittsvolum	3.23M
Markedsverdi	588.05M
EPS	HKD0 ( 2023-08-31 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-0.830
ATR14	HKD0.0270 (0.40%)

Volum Korrelasjon

Lang: 0.10 (neutral)

Kort: 0.41 (neutral)

Signal:(42.035) Neutral

Sirnaomics Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sirnaomics Ltd. Korrelasjon - Valuta/Råvare

-0.49
( neutral )

-0.40
( neutral )

0.00
( neutral )

-0.63
( weak negative )

-0.06
( neutral )

-0.35
( neutral )

Sirnaomics Ltd. Økonomi

Annual	2023
Omsetning:	HKD40 000.00
Bruttogevinst:	HKD40 000.00 (100.00 %)
EPS:	HKD-1.030

FY	2023
Omsetning:	HKD40 000.00
Bruttogevinst:	HKD40 000.00 (100.00 %)
EPS:	HKD-1.030

FY	2022
Omsetning:	HKD0
Bruttogevinst:	HKD0 (0.00 %)
EPS:	HKD-1.160

Financial Reports:

No articles found.

Sirnaomics Ltd.

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.